A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single and Multiple Oral Dose of TAK-418 in Healthy Female Participants

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-05-30

Study Completion Date

2018-12-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to characterize safety and tolerability of TAK-418 in non-Japanese and Japanese healthy female participants when administered at single or multiple (once daily \[QD\]) oral doses.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of TAK-123 After Intravenous Infusion in Japanese Healthy Adult Male Participants

NCT04155567

Healthy Volunteers

COMPLETED PHASE1

A Study of TAK-227 in Healthy Adults

NCT05818956

Healthy Volunteers

COMPLETED PHASE1

Pharmacokinetics of Oral Capsule in Healthy Japanese vs. Caucasian Subjects

NCT03198624

Safety Issues Pharmacokinetics

COMPLETED PHASE1

A Single- and Multiple-Dose Study of the Pharmacokinetics of TAK-491 in Healthy Chinese Participants

NCT02541669

Healthy Volunteer

COMPLETED PHASE1

A Pharmacokinetic Study of TAK-438 in Healthy Adult Chinese Participants

NCT03085836

Healthy Participants

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The drug being tested in this study is called TAK-418. This study will assess the safety, tolerability, PK and PD of single and multiple rising doses of TAK-418 in healthy Japanese or non-Japanese females.

The study will enroll approximately 48 participants in 6 cohorts and each cohort will have 8 participants. The study will include 2 parts: single rising dose (SRD) in Cohort 1 and multiple rising dose (MRD) in Cohorts 2 to 6. Cohort 3 will include cerebrospinal fluid (CSF) collection. Participants will be randomly assigned (by chance, like flipping a coin) to one of the 6 cohorts.

This two-center trial will be conducted in the United States. The overall time to participate in Cohort 1 of this study is approximately 105 days and 98 days in Cohort 2. Participants will be contacted by telephone 14 days after last dose of study drug for a follow-up assessment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Volunteers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

OTHER

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Non-Japanese Cohort 1: TAK-418 120 mg and TAK-418 160 mg

TAK-418 120 milligram (mg) or TAK-418 matching placebo, capsule, orally, once on Day 1 of Period A followed by a minimum of 14 days of washout period, followed by TAK-418 160 mg or TAK-418 matching placebo, capsule, orally, once on Day 1 of Period B. The actual TAK-418 dose for Period B will be determined based on safety, tolerability, and PK data available from the previous dose in Period A.

Group Type EXPERIMENTAL

TAK-418

Intervention Type DRUG

TAK-418 capsules.

TAK-418 Matching Placebo

Intervention Type DRUG

TAK-418 matching placebo capsules.

Non-Japanese Cohort 2: TAK-418 20 mg

TAK-418 20 mg or TAK-418 matching placebo, capsule, orally, once daily for 10 days.

Group Type EXPERIMENTAL

TAK-418

Intervention Type DRUG

TAK-418 capsules.

TAK-418 Matching Placebo

Intervention Type DRUG

TAK-418 matching placebo capsules.

Non-Japanese Cohort 3: TAK-418 40 mg

TAK-418 40 mg or TAK-418 matching placebo, capsule, orally, once daily for 10 days. The actual TAK-418 dose for Cohort 3 will be determined based on safety, tolerability, and PK data available from the previous doses.

Group Type EXPERIMENTAL

TAK-418

Intervention Type DRUG

TAK-418 capsules.

TAK-418 Matching Placebo

Intervention Type DRUG

TAK-418 matching placebo capsules.

Non-Japanese Cohort 4: TAK-418 60 mg

TAK-418 60 mg or TAK-418 matching placebo, capsule, orally, once daily for 10 days. The actual TAK-418 dose for Cohort 4 will be determined based on safety, tolerability, and PK data available from the previous doses.

Group Type EXPERIMENTAL

TAK-418

Intervention Type DRUG

TAK-418 capsules.

TAK-418 Matching Placebo

Intervention Type DRUG

TAK-418 matching placebo capsules.

Japanese Cohort 5: TAK-418 20 mg

TAK-418 20 mg or TAK-418 matching placebo, capsule, orally, once daily for 10 days. The actual TAK-418 dose for Cohort 5 will be determined based on safety, tolerability, and PK data available from the previous doses.

Group Type EXPERIMENTAL

TAK-418

Intervention Type DRUG

TAK-418 capsules.

TAK-418 Matching Placebo

Intervention Type DRUG

TAK-418 matching placebo capsules.

Japanese Cohort 6: TAK-418 40 mg

TAK-418 40 mg or TAK-418 matching placebo, capsule, orally, once daily for 10 days. The actual TAK-418 dose for Cohort 6 will be determined based on safety, tolerability, and PK data available from the previous doses.

Group Type EXPERIMENTAL

TAK-418

Intervention Type DRUG

TAK-418 capsules.

TAK-418 Matching Placebo

Intervention Type DRUG

TAK-418 matching placebo capsules.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TAK-418

TAK-418 capsules.

Intervention Type DRUG

TAK-418 Matching Placebo

TAK-418 matching placebo capsules.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Has a body mass index (BMI) greater than or equal to (\>=) 18.5 and less than or equal to (\<=) 30.0 kilogram per square meter (kg/m\^2) at the Screening Visit. (Cohorts 1 to 4 only).
2. Is a nonsmoker who has not used tobacco- or nicotine-containing products (example, nicotine patch) for at least 6 months before administration of the first dose of trial drug or invasive procedure.
3. The participant either is of nonchildbearing potential, OR, if of childbearing potential, is using a highly effective method of contraception with low user dependency during the entire duration of the study.

For Cohorts 5 and 6 (Japanese participants) only:

1\. Has a BMI \>=18.0 and \<= 26.0 kg/m\^2, at the Screening Visit.

Exclusion Criteria

1. Has a positive test result for hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV), or human immunodeficiency virus (HIV) antibody/antigen, at Screening.
2. Had major surgery, donated or lost 1 unit of blood (approximately 500 milliliter \[mL\]) within 4 weeks before the Screening Visit.
3. Has a history of alcohol consumption exceeding 2 standard drinks per day on average (1 glass is approximately equivalent to beer \[354 mL/12 ounces\], wine \[118 mL/4 ounces\], or distilled spirits \[29.5 mL/1 ounce\] per day).
4. Consumes excessive amounts, defined as greater than 6 servings (1 serving is approximately equivalent to 120 mg of caffeine) of coffee, tea, cola, energy drinks, or other caffeinated beverages per day.
5. Has a substance abuse disorder.
6. Has risk of suicide according to the investigator's clinical judgment per Columbia-Suicide Severity Rating Scale (C-SSRS) at Screening or has made a suicide attempt in the 6 months before Screening.
7. Has luteinizing hormone (LH), follicle-stimulating hormone (FSH), or estradiol levels that are clinically abnormal.
8. Has a resting heart rate outside of the range of 50 to 100 beats per minute, confirmed on repeat testing within a maximum of 30 minutes, at the Screening Visit or Check-in (Day -1).

For Cohort 3 only (includes CSF sample collection):

1. Has had CSF collection performed within 30 days before Check-in (Day -1).
2. Has significant vertebral deformities (scoliosis or kyphosis) that, in the opinion of the investigator, may interfere with the lumbar puncture procedure.
3. Has a local infection at the puncture site.
4. Has thrombocytopenia or other suspected bleeding tendencies noted before the procedure.
5. Has developed signs and symptoms of spinal radiculopathy, including lower extremity pain and paresthesia.
6. Has any focal neurological deficit that might suggest an increase in intracranial pressure.
7. Has any abnormal finding on ophthalmological assessment/fundoscopy indicative of raised intracranial pressure (that is, optic disc swelling/edema; or \[uncontrolled\] hypertensive retinopathy).
8. Regularly has moderate-to-severe headaches requiring analgesics.
9. Has any bleeding abnormality or history of bleeding abnormalities.
10. Has abnormal coagulation tests (prothrombin time \[PT\]/international normalized ratio \[INR\], partial thromboplastin time \[PTT\]) at Screening.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes